AARD

Aardvark Therapeutics Inc

Sep 16 • 04:00PM ET

10.26

+0.31 3.12 %

Healthcare • Biotechnology • USA • NASD

Held by: VTI IWM VXF VTWO IWN IWO IWC RSSL VTWG VTWV

Index	RUT	P/E	-	EPS (ttm)	-1.69	Insider Own	43.00%	Shs Outstand	21.69M	Perf Week	29.71%
Market Cap	222.61M	Forward P/E	-	EPS next Y	-3.02	Insider Trans	0.39%	Shs Float	12.37M	Perf Month	-4.82%
Enterprise Value	81.44M	PEG	-	EPS next Q	-0.76	Inst Own	23.04%	Short Float	5.38%	Perf Quarter	-5.44%
Income	-36.64M	P/S	-	EPS this Y	45.98%	Inst Trans	6.78%	Short Ratio	6.29	Perf Half Y	10.80%
Sales	0.00M	P/B	1.63	EPS next Y	-8.48%	ROA	-46.77%	Short Interest	0.67M	Perf YTD	-28.30%
Book/sh	6.31	P/C	1.57	EPS next 5Y	14.17%	ROE	-110.36%	52W High	19.58 -47.60%	Perf Year	-
Cash/sh	6.54	P/FCF	-	EPS past 3/5Y	-22.31% -	ROIC	-26.71%	52W Low	4.88 110.25%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	10.98% 8.77%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	46.68%	Oper. Margin	-	ATR (14)	0.89	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	14.04	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	55.77	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	14.04	EPS Q/Q	68.88%	SMA20	14.95%	Beta	-	Target Price	32.60
Payout	-	Debt/Eq	0.00	Sales Q/Q	-	SMA50	-6.04%	Rel Volume	2.13	Prev Close	9.95
Employees	22	LT Debt/Eq	0.00	Earnings	Aug 13 AMC	SMA200	-5.04%	Avg Volume	105.82K	Price	10.26
IPO	Feb 13, 2025	Option/Short	No / Yes	EPS/Sales Surpr.	-10.00% -	Trades		Volume	225,389	Change	3.12%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-30-25	Initiated	H.C. Wainwright	Buy	$40
Mar-10-25	Initiated	RBC Capital Mkts	Outperform	$21
Mar-10-25	Initiated	Morgan Stanley	Overweight	$29
Mar-10-25	Initiated	Cantor Fitzgerald	Overweight	$50
Mar-10-25	Initiated	BofA Securities	Buy	$22

Sep-10-25 09:22PM	LB Pharmaceuticals raises $285 million in US IPO (Reuters)
Sep-04-25 08:00AM	Aardvark Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) (GlobeNewswire)
Aug-27-25 04:10PM	Aardvark Therapeutics to Present at Upcoming Investor Conferences in September (GlobeNewswire) -5.67% -5.56%
Aug-13-25 04:10PM	Aardvark Therapeutics Reports Second Quarter 2025 Financial Results and Provides Pipeline and Business Updates (GlobeNewswire) +11.55%
Aug-12-25 08:00AM	Aardvark Therapeutics Announces ARD-201 Preclinical Obesity Data Showing Significant Weight Loss as a Monotherapy, Enhancement of GLP-1RA Therapy in Combination, and Effective Maintenance Following Discontinuation of GLP-1RA Therapy (GlobeNewswire) -9.96%
08:00AM	Loading…
Jul-18-25 08:00AM	Aardvark Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(C)(4) (GlobeNewswire)
Jul-15-25 07:30AM	OSR Holdings Appoints Dr. Andreas Niethammer as Chief Medical Officer of Vaximm AG, an OSR Company (PR Newswire)
Jul-01-25 05:31PM	Aardvark's Hunger-Suppressing Drug Promises Weight Loss Without GI Distress (Benzinga)
Jun-24-25 08:00AM	Aardvark Therapeutics to Join Prader-Willi Syndrome Community at the 2025 United in Hope Conference (GlobeNewswire) +18.23%
Jun-03-25 09:55AM	Wall Street Analysts Think Aardvark Therapeutics, Inc. (AARD) Could Surge 180.77%: Read This Before Placing a Bet (Zacks)
May-19-25 04:10PM	Aardvark Therapeutics Bolsters Leadership Team with Strategic Hires Across Scientific, Commercial, Regulatory and Legal Functions (GlobeNewswire) +5.46% +5.47%
May-14-25 04:10PM	Aardvark Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights (GlobeNewswire) -13.81%
May-07-25 04:05PM	Aardvark Therapeutics to Present at Upcoming Investor Conferences in May (GlobeNewswire)
Mar-31-25 04:10PM	Aardvark Therapeutics Reports Full Year 2024 Financial Results and Provides Business Highlights (GlobeNewswire) +10.39%
Mar-27-25 04:18PM	Soleno Surges Into Breakout On Hard-Won Obesity-Tied Approval, But Aardvark Reverses Lower (Investor's Business Daily) -5.52% -13.03%
09:20AM	Loading…
Mar-21-25 09:20AM	Soleno Therapeutics: FDA Approval May Prove To Be A Pyrrhic Victory (SeekingAlpha) +7.95%
Mar-14-25 11:25AM	Aardvark Therapeutics, Inc. Common Stock (AARD): Among Top Insider Purchases Last Month (Insider Monkey)
Mar-03-25 02:55PM	Aardvark Therapeutics (AARD): Among Stocks With At Least $10 Million In Insider Spending Recently (Insider Monkey)
Feb-12-25 10:38PM	Aardvark Therapeutics Announces Pricing of Initial Public Offering (GlobeNewswire)

Aardvark Therapeutics, Inc. operates as a biotechnology company. It engages in the development of a novel, small-molecule therapeutics for the treatment of metabolic diseases. The company was founded by Tien Lee in 2017 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Lee Tien-Li	Chief Executive Officer	Sep 15 '25	Buy	9.66	10,000	96,624	1,543,384	Sep 16 06:15 AM
VICKERS VENT GLB DEEP-TECH FND	Director	Sep 15 '25	Proposed Sale	9.02	10,360	93,413		Sep 15 04:05 PM
Lee Tien-Li	Chief Executive Officer	Sep 10 '25	Buy	7.91	9,000	71,212	1,522,384	Sep 12 08:28 PM
Lee Tien-Li	Chief Executive Officer	Sep 11 '25	Buy	7.82	6,000	46,926	1,528,384	Sep 12 08:28 PM
Lee Tien-Li	Chief Executive Officer	Sep 12 '25	Buy	8.50	5,000	42,516	1,533,384	Sep 12 08:28 PM
Sun Nelson	Chief Financial Officer	Sep 09 '25	Buy	8.07	6,000	48,440	105,484	Sep 10 05:36 PM
VICKERS VENT GLB DEEP-TECH FND	Director	Sep 02 '25	Proposed Sale	8.51	20,000	170,118		Sep 02 04:05 PM
Lee Tien-Li	Chief Executive Officer	Aug 28 '25	Option Exercise	4.24	17,209	72,966	1,513,384	Aug 29 04:05 PM
VICKERS VENT GLB DEEP-TECH FND	Director	Aug 28 '25	Proposed Sale	8.72	27,691	241,565		Aug 28 04:36 PM
Decheng Capital Global Life Sc	10% Owner	Feb 14 '25	Buy	16.00	1,250,000	20,000,000	2,958,887	Feb 19 05:44 PM
Lee Tien-Li	Chief Executive Officer	Feb 14 '25	Buy	16.00	16,542	264,672	1,496,175	Feb 19 04:35 PM
Sun Nelson	Chief Financial Officer	Feb 14 '25	Buy	16.00	10,000	160,000	99,484	Feb 19 04:30 PM
Cormorant Asset Management, LP	Former 10% Owner	Feb 14 '25	Buy	16.00	187,500	3,000,000	987,689	Feb 19 04:02 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

AARD

Aardvark Therapeutics Inc

Upgrade your FINVIZ experience